BCRX vs. NK, NVAX, RLAY, IMTX, RGNX, KYTX, CABA, CRGX, SRRK, and PRME
Should you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include NantKwest (NK), Novavax (NVAX), Relay Therapeutics (RLAY), Immatics (IMTX), REGENXBIO (RGNX), Kyverna Therapeutics (KYTX), Cabaletta Bio (CABA), CARGO Therapeutics (CRGX), Scholar Rock (SRRK), and Prime Medicine (PRME). These companies are all part of the "medical" sector.
BioCryst Pharmaceuticals (NASDAQ:BCRX) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
BioCryst Pharmaceuticals received 201 more outperform votes than NantKwest when rated by MarketBeat users. Likewise, 66.29% of users gave BioCryst Pharmaceuticals an outperform vote while only 53.85% of users gave NantKwest an outperform vote.
85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 4.4% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 71.7% of NantKwest shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
BioCryst Pharmaceuticals has a net margin of -68.36% compared to NantKwest's net margin of -76,658.58%. BioCryst Pharmaceuticals' return on equity of 0.00% beat NantKwest's return on equity.
BioCryst Pharmaceuticals presently has a consensus target price of $13.29, suggesting a potential upside of 184.49%. Given BioCryst Pharmaceuticals' higher probable upside, equities analysts plainly believe BioCryst Pharmaceuticals is more favorable than NantKwest.
NantKwest has lower revenue, but higher earnings than BioCryst Pharmaceuticals. NantKwest is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
BioCryst Pharmaceuticals has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, suggesting that its share price is 161% more volatile than the S&P 500.
In the previous week, BioCryst Pharmaceuticals had 7 more articles in the media than NantKwest. MarketBeat recorded 7 mentions for BioCryst Pharmaceuticals and 0 mentions for NantKwest. BioCryst Pharmaceuticals' average media sentiment score of 0.39 beat NantKwest's score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.
Summary
BioCryst Pharmaceuticals beats NantKwest on 12 of the 17 factors compared between the two stocks.
Get BioCryst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCryst Pharmaceuticals Competitors List
Related Companies and Tools
